目的 探讨天舒胶囊联合舒马普坦治疗偏头痛的临床疗效。方法 选取2018年3月-2019年3月在平顶山市第二人民医院进行治疗的88例偏头痛患者，根据用药的差别分为对照组（44例）和治疗组（44例）。对照组口服琥珀酸舒马普坦片，25 mg/次，1次/d；治疗组在对照组基础上口服天舒胶囊，1.36 g/次，3次/d。两组均经过4周治疗后进行效果比较。观察两组的临床疗效，比较两组治疗前后相关评分、血清学指标的变化情况。结果 经过治疗，对照组有效率为81.82%，显著低于治疗组97.73%，两组比较差异有统计学意义（P<0.05）。治疗后，两组头痛程度、头痛发作次数、头痛持续时间和头痛伴随症状等评分均较治疗前显著降低，同组治疗前后比较差异具有统计学意义（P<0.05）；且治疗后，治疗组这些症候评分明显低于对照组，两组比较差异具有统计学意义（P<0.05）。两组PSQI评分、GQOLI-74评分、VAS评分均较治疗前显著改善，同组治疗前后比较差异具有统计学意义（P<0.05）；且治疗后，治疗组这些相关量表评分的改善程度优于对照组，两组比较差异具有统计学意义（P<0.05）。两组血清环氧化酶-2（COX-2）、神经元特异性烯醇酶（S-NSE）、基质金属蛋白酶-9（MMP-9）、血栓素B2（TXB2）、5-羟色胺（5-HT）水平均较治疗前显著下降，而β-内啡肽（β-EP）水平均显著升高，同组治疗前后比较差异具有统计学意义（P<0.05）；治疗后，治疗组这些血清学指标改善程度优于对照组，两组比较差异具有统计学意义（P<0.05）。结论 天舒胶囊联合舒马普坦治疗偏头痛具有较好的临床疗效，可有效改善患者临床症状，改善机体相关血清学指标水平，提高患者睡眠及生活质量，具有一定的临床推广应用价值。

Objective To explore the clinical effect of Tianshu Capsules combined with sumatriptan in treatment of migraine. Methods Patients (88 cases) with migraine in Pingdingshan Second People's Hospital from March 2018 to March 2019 were divided into control (44 cases) and treatment (44 cases) groups based on different treatments. Patients in the control group were po administered with Sumatriptan Succinate Tablets, 25 mg/time, once daily. Patients in the treatment group were po administered with Tianshu Capsules on the treatment group, 1.36 g/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the changes of related scores and serological indexes before and after treatment in two groups were compared. Results After treatment, the clinical efficacy and in the control and treatment groups was 81.82% and 97.73% respectively, and there were differences between two groups (P<0.05). After treatment, scores of headache severity, headache attack times, headache duration and headache accompanying symptoms in both groups were significantly lower than those before treatment, and there were differences in the same group (P<0.05). After treatment, these symptom scores were significantly lower in the treatment group than those in the control group, and there were differences between two groups (P<0.05). After treatment, PSQI score, GQOLI-74 score, and VAS score were significantly improved compared with those before treatment, and there were differences in the same group (P<0.05). After treatment, the improvement of these scales in the treatment group were better than those in the control group, and there were differences between two groups (P<0.05). After treatment, COX-2, S-NSE, MMP-9, TXB2, and 5-HT in two groups were significantly decreased, but β-EP was significantly increased, and there were differences in the same group (P<0.05). After treatment, these serological indicators improved better in the treatment group than those in the control group, and there were differences between two groups (P<0.05). Conclusion Tianshu Capsules combined with sumatriptan has significant effect in treatment of migraine, and can effectively improve the clinical symptoms, and also can improve the level of related serological indicators, and improve the sleep quality and life of patients.

R971